Sign Up to like & get
recommendations!
2
Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.847556
Abstract: New targeted chemotherapy agents greatly improved five-year survival in NSCLC patients, but which were susceptible to drug resistance. NVP-AUY922, terminated in phase II clinical trials, exhibited promising anti-NSCLC (non-small-cell lung cancer) activity targeting to Hsp90N…
read more here.
Keywords:
hsp90n;
nvp auy922;
complex crystal;
auy922 ... See more keywords